ENDRA Life Sciences Inc.
NDRA
$6.46
$1.1922.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.70M | 4.37M | 3.91M | 6.46M | 6.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.65M | 6.47M | 5.76M | 8.44M | 8.58M |
| Operating Income | -6.65M | -6.47M | -5.76M | -8.44M | -8.58M |
| Income Before Tax | -5.92M | -7.30M | -7.03M | -8.01M | -8.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.92 | -7.30 | -7.03 | -8.01 | -8.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.92M | -7.30M | -7.03M | -8.01M | -8.77M |
| EBIT | -6.65M | -6.47M | -5.76M | -8.44M | -8.58M |
| EBITDA | -6.61M | -6.43M | -5.72M | -8.39M | -8.53M |
| EPS Basic | -5.92 | -7.75 | -8.52 | -13.35 | -20.79 |
| Normalized Basic EPS | -3.72 | -4.85 | -5.33 | -11.91 | -16.56 |
| EPS Diluted | -5.98 | -7.75 | -8.52 | -13.35 | -20.79 |
| Normalized Diluted EPS | -3.75 | -4.85 | -5.33 | -11.91 | -16.56 |
| Average Basic Shares Outstanding | 4.40M | 3.79M | 3.15M | 2.58M | 2.06M |
| Average Diluted Shares Outstanding | 5.55M | 3.79M | 3.15M | 2.58M | 2.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |